Clinical practice has changed since the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), with the discovery of EGFR driver gene mutations in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.